Skip to main content

Market Overview

What Drove Merck's Keytruda Shortfall In Q4

What Drove Merck's Keytruda Shortfall In Q4

Merck & Co., Inc.'s (NYSE: MRK) shares have underperformed the broader market and the pharma sector per se, and one among the two factors that have led to weakness is soft sales for its wonder cancer drug Keytruda in the fourth quarter.

The Merck Analyst

JPMorgan analyst Chris Schott maintained an Overweight rating and $98 price target for Merck shares in a note released Monday.

The Merck Thesis

Overall, Keytruda concentration has emerged a key controversy on the Merck story but most of the issues that led to the shortfall are one time in nature, Schott said in the note. The analyst said Keytruda sales came in at $3.11 billion in the fourth quarter, about $169 million shy of the consensus.

Keytruda sales in the European Union suffered due to a price adjustment tied to first-line non-small cell lung cancer, or NSCLC, reimbursement decisions in France, Italy and Spain. However, Keytruda now has access to a significant growth opportunity in first-line NSCLC in all major EU countries.

Keytruda sales took a small hit from an anticipated price cut in Japan that led to destocking this quarter, according to Schott. The analyst expects depressed sales in the region yet again in the first quarter ahead of a second planned cut in April. That said, the analyst sees this as transitory, given robustness in underlying volume and demand.

See Also: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Outside of the Keytruda softness, the analyst attributed the pullback to investor skepticism on the longer-term prospects for Keytruda sales amid growing Keytruda sales concentration, the Street's uneasiness over the company's late-stage pipeline and the NewCo spin plans announced recently.

"[W]e feel very comfortable with the stock setup for 2020 as we anticipate a return of strong Keytruda performance throughout the year and see a number of pipeline updates, and with valuation that screens increasingly attractive vs peers and the broader market," Schott wrote in the note.

MRK Price Action

Merck shares were slipping 1.8% to $80.80 at time of publication.

Photo courtesy of Merck.

Latest Ratings for MRK

Apr 2021SVB LeerinkMaintainsOutperform
Nov 2020BernsteinReinstatesOutperform
Oct 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings


Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Chris Schott JPMorgan KeytrudaAnalyst Color Biotech Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at